Skip to main content
SpringerLink
Log in

Zoledronic acid (ZOMETA): a significant improvement in the treatment of Bone metastases

  • Asco 2005
  • Published:
Pathology & Oncology Research

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Coleman RE: Metastatic bone disease: clinical features, patho physiology and treatment strategies. Cancer Treat Rev 27: 165–176, 2001

    Article  PubMed  CAS  Google Scholar 

  2. Russell RG, Rogers MJ: Bisphosphonates: From the laboratory to the clinic and back again. Bone 25: 97–106, 1999

    Article  PubMed  CAS  Google Scholar 

  3. Hurst M, Noble S: Clodronate: A review of its use in breast cancer. Drugs Aging 15: 143–167, 1999

    Article  PubMed  CAS  Google Scholar 

  4. Theriault RL, Lipton A, Hortobagyi GN, et al: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial-Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846–854, 1999

    PubMed  CAS  Google Scholar 

  5. Gordon D, Rosen L, Coleman RE, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate in treatment of skeletal complications in patients with advanced multiple myeloma of breast cancer, Proc Am Soc Clin Oncol22: 47, 2003 (abstr 188)

    Google Scholar 

  6. Perry CM, Figgitt DP: Zoledronic acid: A review of its use in patients with advanced cancer. Drugs 64: 1197–1211, 2004

    Article  PubMed  CAS  Google Scholar 

  7. Kohno N, Aogi K, Minami H, et al: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23: 3314–3321, 2005

    Article  PubMed  CAS  Google Scholar 

  8. Seneratne SG, Colston KW: Direct effects of bisphosphonates on breast cancer cells. Breast Cancer Res 4: 18–23, 2002

    Article  Google Scholar 

  9. Powles T, McCloskey E, Kurkilahti M: Oral clodronate for adjuvant treatment of operable breast cancer: results of a randomized, double-blind, placebo-controlled multicenter trial. Proc Am Soc Clin Oncol 23: 9, 2004 (abstr 528)

    Google Scholar 

  10. Jaschke A, Basiert G, Solomayer EF, et al: Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow — a longtime follow-up. Proc Am Soc Clin Oncol 23: 9, 2004 (abstr 529)

    Google Scholar 

  11. Coleman R, Gralow J, Bell R, Lipton A: Zoledronic acid is being investigated for the prevention of bone metastases in patients with early stage cancer. 7th workshop on Bisphosphonates, 24–26 March 2004, Davos, Switzerland (abstr 60)

    Google Scholar 

  12. Brufsky A, Harker GW, Beck J, et al: Zoledronic acid for prevention of cancer treatment induced bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: preliminary results of the Z-FAST trial. 27th Annual San Antonio Breast Cancer Symposium 2004, San Antonio (abstr 1114)

  13. Brufsky A, Harker W, Beck J, et al: Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let): 12 mos BMD results of the FAST trial. ASCO Annual Meeting, Orlando, 2005 (abstr 533)

  14. Botteman MF, Aapro MS, Hay JW, et al: Cost effectiveness of intravenous (IV) zoledronic acid vs other IV bisphosphonates for the prevention of bone complications in breast cancer patients with bone metastases: A Markov model from the UK perspective. ASCO Annual Meeting, Orlando, 2005 (abstr 721)

  15. Body J, Lichinitser M, Tjulandin S, et al: Effect of oral ibandronate versus intravenous (i.v.) zoledronic acid on markers of bone resorption with breast cancer and bone metastases: Results from a comparative phase III trial. ASCO Annual Meeting, Orlando, 2005 (abstr 534)

  16. Lipton A, Hei Y, Coleman R, et al: Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. ASCO Annual Meeting, Orlando, 2005 (abstr 532)

  17. Jung J, Hwang G, Lee Y, et al: Pamidronate as adjuvant treatment for prevention of bone metastasis in breast cancer. ASCO Annual Meeting, Orlando, 2005 (abstr 888)

  18. Hortobagyi GN: Progress in the management of bone metastases: One continent at a time? J Clin Oncol 23, 1–3, 2005

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, St Imre Hospital, Budapest, Hungary

    Zsuzsanna Nagy

Authors
  1. Zsuzsanna Nagy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagy, Z. Zoledronic acid (ZOMETA): a significant improvement in the treatment of Bone metastases. Pathol. Oncol. Res. 11, 186–187 (2005). https://doi.org/10.1007/BF02893400

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02893400

Keywords

Search

Navigation